A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study

Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: 5b764e60fe03a935186257f7f3509e48b2ef4b0c
First added on: Feb 07, 2025